(+)-α-Lipoic acid

Catalog No.S3998 Synonyms: (R)-(+)-α-Lipoic acid, α-Lipoic acid, Alpha-Lipoic acid

For research use only.

(+)-α-Lipoic acid ((R)-(+)-α-Lipoic acid, α-Lipoic acid, Alpha-Lipoic acid), a physiological form of thioctic acid, is a strong antioxidant that relieves diabetic neuropathic symptoms. It shows superior antioxidative effects to its racemate. R(+)-α-lipoic acid is an essential cofactor of mitochondrial enzyme complexes. R(+)-α-lipoic acid inhibits NF-κB-dependent HIV-1 LTR activation.

(+)-α-Lipoic acid Chemical Structure

CAS No. 1200-22-2

Purity & Quality Control

Choose Selective NF-κB Inhibitors

Other NF-κB Products

Biological Activity

Description (+)-α-Lipoic acid ((R)-(+)-α-Lipoic acid, α-Lipoic acid, Alpha-Lipoic acid), a physiological form of thioctic acid, is a strong antioxidant that relieves diabetic neuropathic symptoms. It shows superior antioxidative effects to its racemate. R(+)-α-lipoic acid is an essential cofactor of mitochondrial enzyme complexes. R(+)-α-lipoic acid inhibits NF-κB-dependent HIV-1 LTR activation.
Targets
NF-κB [2]
()
LTR [1]
()
LTR [2]
()
In vitro

Using L6 myotubes and 3T3-L1 adipocytes as a model of muscle and fat cells in culture, R(+)-α-lipoic acid (R-LA) is shown to increase tyrosine phosphorylation of insulin receptor and IRS-1, to enhance PI 3-kinase and Akt1 activities, to elevate GLUT4 content in the plasma membranes, and to increase glucose uptake into the cells. 3T3-L1 adipocytes possess a low capacity to reduce R-α-lipoic acid and the oxidized isoforms are effective in stimulating glucose transport. R-α-lipoic acid modulates glucose transport by changing intracellular redox status. Insulin receptor is a target of R-LA action[1].

Protocol (from reference)

Cell Research:

[1]

  • Cell lines: 3T3-L1 preadipocytes
  • Concentrations: 250 μM
  • Incubation Time: 2-48 h
  • Method:

    Cells seeded in 12-well plates were incubated for 2–48 h with R-LA (250 μM) and loaded with H2DCF-DA (20 μM) for the last 30 min in PBS containing R-LA. For some experiments cells were washed and incubated with R-LA (0.25-1 μM) and H2DCF-DA (20 μM) for 30 min. Following the treatments, cells were gently scraped by a lifter and suspended in the same media. For detection of intracellular fluorescence, cells were excited using a 488-nm argon-ion laser in a flow cytometer. The dichlorofluorescein (DCF) emission was recorded at 530 nm. Data were collected from at least 20,000 cells.

  • (Only for Reference)

Solubility (25°C)

In vitro

DMSO 41 mg/mL
(198.71 mM)


* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 206.33
Formula

C8H14O2S2

CAS No. 1200-22-2
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1CSSC1CCCCC(=O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01877590 Completed Drug: alpha-lipoic acid Type 2 Diabetes|Coronary Artery Disease|Left Ventricular Mass Wuhan General Hospital of Guangzhou Military Command November 2013 Phase 4
NCT01895699 Completed Other: Contrast agent Contrast Agent|Endothelial Function|Cytokines|Apoptosis of Endothelial Progenitor Cell|Free Radical|Alpha-lipoic Acid Xiang Guang-da|Wuhan General Hospital of Guangzhou Military Command July 2013 Phase 4
NCT02056366 Completed Drug: α-lipoic acid Type 2 Diabetes|Cardiac Autonomic Neuropathy The Catholic University of Korea January 2010 Phase 4

(data from https://clinicaltrials.gov, updated on 2021-09-06)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy (+)-α-Lipoic acid | (+)-α-Lipoic acid supplier | purchase (+)-α-Lipoic acid | (+)-α-Lipoic acid cost | (+)-α-Lipoic acid manufacturer | order (+)-α-Lipoic acid | (+)-α-Lipoic acid distributor